Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Drug Shrinks Lung Cancer Tumours in Mice

Published: Monday, November 09, 2009
Last Updated: Monday, November 09, 2009
Bookmark and Share
A potential new drug for lung cancer has eliminated tumours in 50% of mice in a new study published today in the journal Cancer Research.

In the animals, the drug also stopped lung cancer tumours from growing and becoming resistant to treatment. The authors of the research, from Imperial College London, are now planning to take the drug into clinical trials, to establish whether it could offer hope to patients with an inoperable form of lung cancer.

One in five people with lung cancer have small cell lung cancer and only three per cent of these people are expected to survive for five years. With this form of lung cancer, tumours spread quickly so it is rarely possible to remove the tumours surgically. Because of this, small cell lung cancer is treated with chemotherapy, with or without additional radiotherapy. Initially, the treatment often appears to work, reducing the size of the tumours. However, the tumours usually grow back rapidly and then become resistant to further treatment.

The researchers behind today's study have identified a drug that, in some mice, was able to completely shrink tumours away. In the mouse models, it was also able to stop tumours from growing and it helped other forms of chemotherapy to work more effectively. If the drug proves successful in humans, the researchers hope that it could help patients with this kind of lung cancer to live longer.

In small cell lung cancer, tumours spread quickly because the tumour cells grow and divide faster than normal cells. Previous research carried out by the Imperial team showed that these tumour cells proliferate faster because they are fuelled by a growth hormone called FGF-2. This growth hormone also triggers a survival mechanism in the tumour cells that makes them become resistant to chemotherapy.

In today's study, the researchers looked at the effect of a drug called PD173074, which blocks the receptor that FGF-2 uses to attach to the tumour cells. The drug stopped cancer cells from proliferating and from becoming resistant to treatment in 'test-tube' laboratory models. In one animal model of small cell lung cancer, the drug eliminated tumours in 50% of mice and in a second, similar mouse model, the drug enhanced the effect of standard chemotherapy.

Professor Michael Seckl, corresponding author of the study who heads the Section of Molecular Oncology and Lung Cancer Research at Imperial College London, said: "Lung cancer is the most common cancer killer in the world and over 100 people in the UK are diagnosed with the disease every day. Around one in five of those people will have small cell lung cancer. Although it responds to chemotherapy initially, the tumours soon become resistant to treatment and sadly nearly all people with the disease do not survive.

"We urgently need to develop new treatments for this disease. Our new research in mice suggests that it may be possible to develop the drug PD173074 into a new targeted therapy for small cell lung cancer. We hope to take this drug, or a similar drug that also stops FGF-2 from working, into clinical trials next year to see if it is a successful treatment for lung cancer in humans. An added bonus of this drug is that it could be taken orally, which would make it less invasive than some other forms of cancer therapy," added Professor Seckl.

The researchers first studied the effect of PD173074 in the lab, on cells taken from human tumours. The drug stopped cells from proliferating and prevented FGF-2 from triggering their survival mechanism, so the cells could be killed with standard chemotherapy agents. The effect of the drug was dose-dependent, so the more drug the researchers added to the cells, the less the cells proliferated.

The researchers then studied PD173074 in mice using two different types of human small cell lung cancer tumours. They tested the drug on its own and alongside the standard chemotherapy agent cisplatin, which is frequently used to treat patients with the disease. In the first mouse model, PD173074 given on its own killed off tumours in 50 per cent of the mice and these mice remained disease-free for at least one year. In the second mouse model, both PD173074 and cisplatin alone slowed down tumour growth. When the drugs were combined, they slowed down tumour growth significantly faster than either drug on its own.

The researchers also used PET scanning to show that the drug reduced DNA synthesis in the tumours, which indicates that the drug was preventing cell proliferation. The researchers also found that the rate of cell death, or apoptosis, in the tumours increased after the drug was given to the mice.

PD173074 was developed in 1998 to stop blood vessels from forming around tumours. Today's research is the first to show this drug has a therapeutic effect on tumours in mice.

The research was funded by the Cancer Treatment and Research Trust, Cancer Research UK and the UK Department of Health.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

New Technique Negotiates Neuron Jungle To Target Source Of Parkinson’s Disease
Researchers from Imperial College London and Newcastle University believe they have found a potential new way to target cells of the brain affected by Parkinson’s disease.
Wednesday, September 23, 2015
Using Human Stem Cells To Identify Dangerous Side Effects Of Drugs
Scientists have developed a test that uses cells from a single donor's blood to predict whether a new drug will cause a severe reaction in humans.
Monday, March 09, 2015
Switch that Enables Salmonella to Sabotage Host Cells Revealed in new Study
A new switch that enables Salmonella bacteria to sabotage host cells is revealed in a study published in the journal Science.
Friday, April 23, 2010
Research Reveals Exactly How Coughing is Triggered by Environmental Irritants
Scientists identify the reaction inside the lungs that can trigger coughing when a person is exposed to particular irritants in the air.
Monday, November 23, 2009
Scientists Discover new Genetic Variation that Contributes to Diabetes
Study identifies a genetic variation in people with type 2 diabetes that affects how the body's muscle cells respond to the hormone insulin.
Tuesday, September 08, 2009
Urine Samples could be Used to Predict Responses to Drugs, Say Researchers
Researchers show possibility to predict how different individuals would deal with one drug by looking at metabolites in their urine.
Tuesday, August 11, 2009
Schizophrenia Linked to Signaling Problems in New Brain Study
The study supports the theory that abnormalities in the way in which cells 'talk' to each other are involved in the disease.
Wednesday, March 04, 2009
Liver Damage in Hepatitis C Patients Could be Treated with Warfarin
The drug warfarin may help prevent liver failure in thousands of people with Hepatitis C, according to new research.
Friday, August 01, 2008
Alzheimer's Disease Patients Show Improvement in Trial of new Drug
A new drug has been shown to improve the brain function of Alzheimer's patients and reduce a key protein associated with the disease in the spinal fluid.
Wednesday, July 30, 2008
Gene Sequence that can make Half of us Fatter is Discovered
Researchers have found a gene sequence linked to an expanding waist line, weight gain and a tendency to develop type 2 diabetes.
Monday, May 05, 2008
Chemical Signature of Manic Depression Discovered by Scientists
People with manic depression have a distinct chemical signature in their brains, according to a new study.
Thursday, February 07, 2008
Targeting Gut Bugs could Revolutionize Future Drugs, say Researchers
Revolutionary new ways to tackle certain diseases could be provided by creating drugs which change the bugs in people's guts.
Monday, February 04, 2008
Research Showing How Drugs Stick to a Key Protein
This information should help scientists to modify the structures of drugs to improve their effectiveness.
Monday, October 17, 2005
Scientific News
Inroads Against Leukemia
Potential for halting disease in molecule isolated from sea sponges.
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.
A Fundamental Protection Mechanism Against Formalin In Mammals is Revealed
Formaldehyde, or formalin, is well known to all of us as a common chemical used in many industrial processes and also as a preservative, remarkably we also produce formaldehyde in our bodies.
Drug Used To Treat HIV Linked to Lower Bone Mass in Newborns
NIH study finds mothers’ use of tenofovir tied to lower bone mineral content in babies.
Bone Risks Linked to Genetic Variants
A large-scale genomic study uncovered novel genetic variants and led researchers to an unexpected gene that affects bone density and fracture risk.
Combo of 3 Antibiotics Can Kill Deadly Staph Infections
Three antibiotics that, individually, are not effective against a drug-resistant staph infection can kill the deadly pathogen when combined as a trio, according to new research.
Microbe Artwork Shows The Limits Of Antibiotics
An Oxford University research fellow has been creating art using bacteria found in the human gut and harvested from faecal samples.
Urine Excretion From Stem Cell-Derived Kidneys
Researchers report a strategy for enabling urine excretion from kidneys grown from stem cells.
Low Dose Beta-Blockers As Effective As High Dose After a Heart Attack?
Heart attack patients live as long – or even longer – on one-quarter the suggested dose.
Antidepressants Plus Blood-Thinners Slow Down Brain Cancer
EPFL scientists have found that combining antidepressants with anticoagulants slows down brain tumors (gliomas) in mice.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos